Postoperative Adjuvant Therapy of HCC Based on PD-1
Status:
Active, not recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
To Hepatocellular carcinoma (HCC), radical resection is still one of the best treatments for
HCC, but the recurrence rate is as high as 70% five years after the operation, and the
prognosis of patients with high-risk recurrence factors such as portal vein tumor thrombus
(PVTT) and microvascular invasion (MVI) is even worse, so it is particularly urgent to find
effective postoperative adjuvant treatment. Immune checkpoint inhibitors(such as PD1) may
improve the prognosis of these patients.